Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors

Clinical Sarcoma Research

Guido Biasco³  Antonio D Pinna²  Giovanni Brandi⁴  Giorgio Ercolani²  Donatella Santini¹  Valentina Indio³  Cristian Lolli⁴  Margherita Nannini⁴  Maristella Saponara³  Fabio Fuligni⁴  Milena Urbini³  Annalisa Astolfi³  Maria A Pantaleo³ 

[1] Pathology Unit, Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy;Department of General Surgery and Transplantation, Sant’Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy;“Giorgio Prodi” Cancer Research Center, University of Bologna, Bologna, Italy;Department of Specialized, Experimental and Diagnostic Medicine, Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

关键词: KIT/PDGFRA wild type;    Gastrointestinal stromal tumors;    DMD;    Dystrophin;   

Others  :  1092821
DOI  :  10.1186/2045-3329-4-9

 received in 2014-06-20, accepted in 2014-07-28,  发布年份 2014

【 摘 要 】

Background

Intragenic deletions of the dystrophin-encoding and muscular dystrophy-associated DMD gene have been recently described in gastrointestinal stromal tumor (GIST), rhabdomyosarcoma (RMS) and leiomyosarcoma (LMS). We evaluated the copy numbers and gene expression levels of DMD in our series of GIST patients who were already studied with wide genome assays, to investigate more fully a correlation between dystrophin status and disease annotations.

Findings

Our study highlighted a recurrent intragenic deletion on chromosome X, involving the DMD gene that codes for human dystrophin in GIST patients. Of 29 KIT/PDGFRA mutant GIST samples, 9 (31%) showed deletions of the DMD gene, which were focal and intragenic in 8 cases, and involved loss of an entire chromosome in one case (GIST_188). DMD loss was seen in only 5 patients with metastasis, whereas 18 out of 20 patients with localized disease had wild-type DMD (P = 0.0004, Fisher exact test). None of the 6 KIT/PDGFRA WT GIST showed DMD alterations.

Conclusions

Our study confirms the presence of DMD deletions only in KIT/PDGFRA mutant GIST and this event is almost associated with metastatic disease. These findings are, of course, quite preliminary but support development of potential therapeutic strategies that target and restore DMD function in the treatment of metastatic GIST.

【 授权许可】

   
2014 Pantaleo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Wang Y, Marino-Enriquez A, Bennett RR, Zhu M, Shen Y, Eilers G, Lee JC, Henze J, Fletcher BS, Gu Z, Fox EA, Antonescu CR, Fletcher CD, Guo X, Raut CP, Demetri GD, van de Rijn M, Ordog T, Kunkel LM, Fletcher JA: Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet 2014, 46:601-606.
• [2]Astolfi A, Nannini M, Pantaleo MA, Di Battista M, Heinrich MC, Santini D, Catena F, Corless CL, Maleddu A, Saponara M, Lolli C, Di Scioscio V, Formica S, Biasco G: A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Lab Invest 2010, 90:1285-1294.
• [3]Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006, 24:4764-4774.
• [4]Liegl B, Kepten I, Le C, Demetri GD, Heinrich MC, Fletcher CDM, Corless CL, Fletcher JA: Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008, 216:64-74.
• [5]Nannini M, Biasco G, Astolfi A, Pantaleo MA: An overview on molecular biology of KIT/PDGFRA wild type (WTWT) gastrointestinal stromal tumours (GIST). J Med Genet 2013, 50:653-661.